{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:39:41Z","timestamp":1790231981367,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,18]],"date-time":"2014-12-18T00:00:00Z","timestamp":1418860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.ijid.2014.12.031","type":"journal-article","created":{"date-parts":[[2015,3,22]],"date-time":"2015-03-22T20:32:13Z","timestamp":1427056333000},"page":"50-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"special_numbering":"C","title":["Repurposing\u2014a ray of hope in tackling extensively drug resistance in tuberculosis"],"prefix":"10.1016","volume":"32","author":[{"given":"Arundhati","family":"Maitra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sad\u00e9","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trupti","family":"Kolvekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padma V.","family":"Devarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan D.","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjib","family":"Bhakta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2014.12.031_bib0410","doi-asserted-by":"crossref","first-page":"e1002464","DOI":"10.1371\/journal.ppat.1002464","article-title":"Tuberculosis and HIV co-infection","volume":"8","author":"Pawlowski","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijid.2014.12.031_bib0415","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nm0307-295","article-title":"From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis","volume":"13","author":"Dorman","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.ijid.2014.12.031_bib0420","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/S0140-6736(10)60410-2","article-title":"Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis","volume":"375","author":"Gandhi","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2014.12.031_bib0425","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1016\/j.socscimed.2009.03.041","article-title":"Drivers of tuberculosis epidemics: the role of risk factors and social determinants","volume":"68","author":"Lonnroth","year":"2009","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.ijid.2014.12.031_bib0430","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/jac\/dkr173","article-title":"Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs","volume":"66","author":"Almeida Da Silva","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0435","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.imbio.2011.07.008","article-title":"Mycobacterium tuberculosis: immune evasion, latency and reactivation","volume":"217","author":"Gupta","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.ijid.2014.12.031_bib0440","first-page":"939","article-title":"The early bactericidal activity of drugs on patients with pulmonary tuberculosis","volume":"121","author":"Jindani","year":"1980","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ijid.2014.12.031_bib0445","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jac\/47.1.117","article-title":"Dormant tubercle bacilli: the key to more effective TB chemotherapy?","volume":"47","author":"Dick","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0450","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1476-5381.2011.01250.x","article-title":"Novel classes of antibiotics or more of the same?","volume":"163","author":"Coates","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ijid.2014.12.031_bib0455","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ijid.2014.12.031_bib0460","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.2174\/15680266113136660166","article-title":"Repurposed drugs in metabolic disorders","volume":"13","author":"Finsterer","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.ijid.2014.12.031_bib0465","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0002-9343(99)00408-8","article-title":"Thalidomide: current and potential clinical applications","volume":"108","author":"Calabrese","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.ijid.2014.12.031_bib0470","doi-asserted-by":"crossref","first-page":"PL309","DOI":"10.1016\/S0024-3205(98)00158-1","article-title":"Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells","volume":"62","author":"Moreland","year":"1998","journal-title":"Life Sci"},{"key":"10.1016\/j.ijid.2014.12.031_bib0475","doi-asserted-by":"crossref","first-page":"e30749","DOI":"10.1371\/journal.pone.0030749","article-title":"Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model","volume":"7","author":"Maiga","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2014.12.031_bib0480","first-page":"590","article-title":"The effects of thalidomide on leprosy reaction","volume":"39","author":"Languillon","year":"1971","journal-title":"Intl J Leprosy"},{"key":"10.1016\/j.ijid.2014.12.031_bib0485","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/08830738060210040801","article-title":"Intractable intracranial tuberculous infection responsive to thalidomide: report of four cases","volume":"21","author":"Schoeman","year":"2006","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ijid.2014.12.031_bib0490","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/jac\/dks405","article-title":"Is repositioning of drugs a viable alternative in the treatment of tuberculosis?","volume":"68","author":"Palomino","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0495","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nrd4001","article-title":"Advances in the development of new tuberculosis drugs and treatment regimens","volume":"12","author":"Zumla","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ijid.2014.12.031_bib0500","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1128\/.61.3.377-392.1997","article-title":"DNA gyrase, topoisomerase IV, and the 4-quinolones","volume":"61","author":"Drlica","year":"1997","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.ijid.2014.12.031_bib0505","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/jac\/44.3.393","article-title":"Activity of moxifloxacin against mycobacteria","volume":"44","author":"Gillespie","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0510","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1128\/AAC.43.1.85","article-title":"Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis","volume":"43","author":"Miyazaki","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0515","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.2165\/00003495-200767140-00007","article-title":"Fluoroquinolones for the treatment of pulmonary tuberculosis","volume":"67","author":"Moadebi","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ijid.2014.12.031_bib0520","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1164\/rccm.200305-682OC","article-title":"The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis","volume":"168","author":"Gosling","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2014.12.031_bib0525","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Consortium REMoxTB. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2014.12.031_bib0710","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1472-9792(08)70010-6","article-title":"Gatifloxacin","volume":"88","year":"2008","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ijid.2014.12.031_bib0715","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1472-9792(08)70016-7","article-title":"Moxifloxacin","volume":"88","year":"2008","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ijid.2014.12.031_bib0530","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1086\/427292","article-title":"Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada","volume":"40","author":"Bozeman","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2014.12.031_bib0535","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1473-3099(03)00671-6","article-title":"Fluoroquinolones, tuberculosis, and resistance","volume":"3","author":"Ginsburg","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2014.12.031_bib0540","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1056\/NEJM200311133492023","article-title":"The rapid development of fluoroquinolone resistance in M. tuberculosis","volume":"349","author":"Ginsburg","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2014.12.031_bib0720","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1128\/AAC.47.2.653-657.2003","article-title":"Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis","volume":"47","author":"Hu","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0725","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1089\/mdr.2006.12.7","article-title":"Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility","volume":"12","author":"Kam","year":"2006","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.ijid.2014.12.031_bib0555","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/35016103","article-title":"A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis","volume":"405","author":"Stover","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2014.12.031_bib0730","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1128\/AAC.37.2.183","article-title":"In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis","volume":"37","author":"Ashtekar","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0560","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.4155\/fmc.11.90","article-title":"Nitroimidazoles for the treatment of TB: past, present and future","volume":"3","author":"Mukherjee","year":"2011","journal-title":"Future Med Chem"},{"key":"10.1016\/j.ijid.2014.12.031_bib0565","doi-asserted-by":"crossref","first-page":"14188","DOI":"10.1073\/pnas.1121497109","article-title":"Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques","volume":"109","author":"Lin","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijid.2014.12.031_bib0735","doi-asserted-by":"crossref","first-page":"11998","DOI":"10.1021\/bi701506h","article-title":"Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate","volume":"46","author":"Hugonnet","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijid.2014.12.031_bib0740","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1128\/AAC.03539-14","article-title":"In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with beta-lactamase inhibitors","volume":"58","author":"Horita","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0570","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1128\/AAC.05690-11","article-title":"Meropenem\u2013clavulanic acid shows activity against Mycobacterium tuberculosis in vivo","volume":"56","author":"England","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0575","doi-asserted-by":"crossref","first-page":"558","DOI":"10.5588\/ijtld.11.0414","article-title":"Clinical use of the meropenem\u2013clavulanate combination for extensively drug-resistant tuberculosis [Case study]","volume":"16","author":"Payen","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2014.12.031_bib0745","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1021\/mp100130b","article-title":"Intestinal absorption mechanism of tebipenem pivoxil, a novel oral carbapenem: involvement of human OATP family in apical membrane transport","volume":"7","author":"Kato","year":"2010","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ijid.2014.12.031_bib0750","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1128\/AAC.03539-14","article-title":"In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with \u03b2-lactamase inhibitors","volume":"58","author":"Horita","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0755","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1183\/09031936.00124312","article-title":"Efficacy and safety of meropenem\u2013clavulanate added to linezolid-containing regimens in the treatment of MDR-\/XDR-TB","volume":"41","author":"De Lorenzo","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijid.2014.12.031_bib0760","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijantimicag.2013.10.010","article-title":"Activity of linezolid-containing regimens against multidrug-resistant tuberculosis in mice","volume":"43","author":"Zhao","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2014.12.031_bib0765","doi-asserted-by":"crossref","first-page":"240","DOI":"10.7883\/yoken.65.240","article-title":"In vitro activity of linezolid against clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains from Beijing, China","volume":"65","author":"Yang","year":"2012","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.ijid.2014.12.031_bib0770","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jac\/dki148","article-title":"Linezolid for the treatment of multidrug-resistant tuberculosis","volume":"56","author":"Fort\u00fan","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0775","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1006\/jmbi.1999.3247","article-title":"Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center","volume":"294","author":"Kloss","year":"1999","journal-title":"J Mol Biol"},{"key":"10.1016\/j.ijid.2014.12.031_bib0610","doi-asserted-by":"crossref","first-page":"e94462","DOI":"10.1371\/journal.pone.0094462","article-title":"Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis","volume":"9","author":"Wallis","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2014.12.031_bib0780","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/jac\/49.2.275","article-title":"Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis","volume":"49","author":"De Logu","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0615","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkr444","article-title":"Clofazimine: current status and future prospects","volume":"67","author":"Cholo","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0785","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.4155\/fmc.11.95","article-title":"Drug repositioning in the treatment of malaria and TB","volume":"3","author":"Nzila","year":"2011","journal-title":"Future Med Chem"},{"key":"10.1016\/j.ijid.2014.12.031_bib0790","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/jac\/43.5.615","article-title":"Antimycobacterial activities of riminophenazines","volume":"43","author":"Reddy","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0795","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","article-title":"Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis","volume":"182","author":"Van Deun","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2014.12.031_bib0800","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jac\/dks389","article-title":"Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"68","author":"Dey","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0805","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.5588\/ijtld.12.0144","article-title":"Systematic review of clofazimine for the treatment of drug-resistant tuberculosis","volume":"17","author":"Gopal","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2014.12.031_bib0810","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1128\/AAC.01696-12","article-title":"Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains","volume":"57","author":"Lim","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0815","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1093\/jac\/dkt089","article-title":"Ivermectin lacks antituberculous activity","volume":"68","author":"Muhammed Ameen","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0820","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tube.2009.07.002","article-title":"New anti-tuberculosis agents amongst known drugs","volume":"89","author":"Lougheed","year":"2009","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.ijid.2014.12.031_bib0660","first-page":"147","article-title":"Mechanisms of anthelmintic action","volume":"19","author":"Sheth","year":"1975","journal-title":"Prog Drug Res"},{"key":"10.1016\/j.ijid.2014.12.031_bib0665","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1086\/320751","article-title":"Successful treatment of metronidazole- and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome","volume":"32","author":"Abboud","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2014.12.031_bib0825","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1021\/jm9010719","article-title":"Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance","volume":"52","author":"de Carvalho","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijid.2014.12.031_bib0830","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1128\/AAC.02542-12","article-title":"Efficacy of nitazoxanide against clinical isolates of Mycobacterium tuberculosis","volume":"57","author":"Shigyo","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0835","doi-asserted-by":"crossref","first-page":"e1000423","DOI":"10.1371\/journal.pcbi.1000423","article-title":"Drug discovery using chemical systems biology: repositioning the safe medicine comtan to treat multi-drug and extensively drug resistant tuberculosis","volume":"5","author":"Kinnings","year":"2009","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.ijid.2014.12.031_bib0840","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/jac\/38.6.1049","article-title":"Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis","volume":"38","author":"Amaral","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0845","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1128\/AAC.47.3.917-922.2003","article-title":"Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis","volume":"47","author":"Ordway","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0850","doi-asserted-by":"crossref","first-page":"e12640","DOI":"10.1371\/journal.pone.0012640","article-title":"The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis","volume":"5","author":"van Soolingen","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2014.12.031_bib0855","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1073\/pnas.0500469102","article-title":"Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs","volume":"102","author":"Weinstein","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijid.2014.12.031_bib0860","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ijantimicag.2012.01.012","article-title":"Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections","volume":"39","author":"Amaral","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2014.12.031_bib0705","first-page":"524","volume":"35","author":"Amaral","year":"2010","journal-title":"Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2014.12.031_bib0865","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1472-9792(08)70028-3","article-title":"Thioridazine","volume":"88","year":"2008","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ijid.2014.12.031_bib0870","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1360-0443.2004.00597.x","article-title":"Does disulfiram have a role in alcoholism treatment today?","volume":"99","author":"Fuller","year":"2004","journal-title":"Addiction"},{"key":"10.1016\/j.ijid.2014.12.031_bib0875","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1128\/AAC.06445-11","article-title":"Anti-tubercular activity of disulfiram, an anti-alcoholism drug, against multi-drug and extensively drug-resistant Mycobacterium tuberculosis isolates","volume":"56","author":"Horita","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0880","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.4049\/jimmunol.179.4.2060","article-title":"Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin","volume":"179","author":"Liu","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.ijid.2014.12.031_bib0885","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1126\/science.1123933","article-title":"Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response","volume":"311","author":"Liu","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.ijid.2014.12.031_bib0890","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(10)61889-2","article-title":"High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial","volume":"377","author":"Martineau","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2014.12.031_bib0895","doi-asserted-by":"crossref","first-page":"e002672","DOI":"10.1136\/bmjopen-2013-002672","article-title":"Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay","volume":"3","author":"Guzman","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijid.2014.12.031_bib0900","doi-asserted-by":"crossref","first-page":"16004","DOI":"10.1073\/pnas.1214188109","article-title":"Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials","volume":"109","author":"Gold","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijid.2014.12.031_bib0905","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.chembiol.2014.02.009","article-title":"DNA replication is the target for the antibacterial effects of nonsteroidal anti-inflammatory drugs","volume":"21","author":"Yin","year":"2014","journal-title":"Chem Biol"},{"key":"10.1016\/j.ijid.2014.12.031_bib0910","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1189\/jlb.4A0214-093RR","article-title":"Characterization of lung inflammation and its impact on macrophage function in aging","volume":"96","author":"Canan","year":"2014","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.ijid.2014.12.031_bib0915","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1128\/AAC.41.5.1004","article-title":"Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium","volume":"41","author":"Collins","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2014.12.031_bib0920","first-page":"193","article-title":"Rapid methods for testing inhibitors of mycobacterial growth. Antibiotic resistance protocols","author":"Evangelopoulos","year":"2010","journal-title":"Springer;"},{"key":"10.1016\/j.ijid.2014.12.031_bib0925","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/jac\/dks056","article-title":"An integrated surrogate model for screening of drugs against Mycobacterium tuberculosis","volume":"67","author":"Gupta","year":"2012","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971214017494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971214017494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T22:50:36Z","timestamp":1598827836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971214017494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":81,"alternative-id":["S1201971214017494"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2014.12.031","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing\u2014a ray of hope in tackling extensively drug resistance in tuberculosis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2014.12.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}